TECENTRIQ®
atezolizumab 840 mg / 1200 mg INJECTION FOR IV USE

What's next?

A treatment option for **PD-L1+ non-small cell lung cancer after surgery and chemo**

PD-L1+ = positive for the biomarker called programmed death-ligand 1.

WHAT IS TECENTRIQ?

TECENTRIQ is a prescription medicine used to treat:

Adults with a type of lung cancer called non-small cell lung cancer (NSCLC).

- **TECENTRIQ may be used alone as a treatment for your lung cancer:**
  - to help prevent your lung cancer from coming back after your tumor(s) has been removed by surgery and you have received platinum-based chemotherapy, **and**
  - you have stage 2 to stage 3A NSCLC (talk to your healthcare provider about what these stages mean), **and**
  - your cancer tests positive for "PD-L1".

It is not known if TECENTRIQ is safe and effective when used:

- in children for the treatment of NSCLC.

SELECT IMPORTANT SAFETY INFORMATION

Possible serious side effects with TECENTRIQ include, but are not limited to, lung problems, intestinal problems, liver problems, hormone gland problems, kidney problems, skin problems, problems in other organs, severe infusion reactions, and complications, including graft-versus-host disease (GVHD), in people who have received a bone marrow (stem cell) transplant that uses donor stem cells (allogeneic).

Please see full Prescribing Information for additional Important Safety Information.

The people depicted herein are not actual patients.



Lung cancer can bring up a lot of emotions.

Talking to your doctor about your options can help you feel more prepared.

YOU HAVE OPTIONS

If your non-small cell lung cancer has not spread outside the lungs, your doctor will likely suggest surgery as your first step on the treatment path.

After surgery, innovative treatments are giving people with non-small cell lung cancer the chance to keep their disease from returning. Your doctor will determine which treatment plan is right for you. Depending on your plan and type of cancer, you may receive chemotherapy, radiation, targeted therapy, and/or immunotherapy.

THE 3-STEP TREATMENT PLAN WITH TECENTRIQ® (atezolizumab): AN OPTION WITH SURGERY, CHEMO, AND IMMUNOTHERAPY

If you have stage 2 to stage 3A non-small cell lung cancer that has tested positive for PD-L1, you and your doctor may decide on treatment with TECENTRIQ immunotherapy as part of your treatment plan.

STEP 1: SURGERY

Surgery is important to remove visible tumor(s), but afterward the cancer sometimes returns because there may be hidden microscopic cancer cells that weren't found during surgery.

STEP 2: CHEMOTHERAPY

Chemotherapy is a critical element of treatment after surgery. It aims to destroy cancer cells that were not removed by surgery by stopping or slowing their growth, either by killing them or stopping them from making new cells. Even after chemotherapy, some cancer cells may become resistant to treatment and survive, grow, or return. TECENTRIQ immunotherapy may be helpful as a third step.

STEP 3: TECENTRIQ IMMUNOTHERAPY

In this final step of treatment, TECENTRIQ works with your immune system to help you fight PD-L1+ non-small cell lung cancer. TECENTRIQ is an immunotherapy that can help reactivate the immune system so it can recognize microscopic cancer cells in the body. This helps your immune system target and attack your cancer. TECENTRIQ may also affect normal cells.

Talk with your doctor about how long you will receive chemotherapy after surgery. Treatment with TECENTRIQ may last for up to 1 year, and you will receive TECENTRIQ every 2, 3, or 4 weeks, depending on which treatment schedule is best for you.

PD-L1+ = positive for the biomarker called programmed death-ligand 1.

SELECT IMPORTANT SAFETY INFORMATION

What is the most important information about TECENTRIQ?

TECENTRIQ can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or life-threatening and can lead to death. You can have more than one of these problems at the same time. These problems may happen anytime during your treatment or even after your treatment has ended.

Please see full Prescribing Information and Medication Guide for additional Important Safety Information.

TECENTRIQ MAY PREVENT YOUR PD-L1+ NON-SMALL CELL LUNG CANCER FROM COMING BACK

In a clinical trial of TECENTRIQ that included 476 people with stage 2 to stage 3A non-small cell lung cancer (NSCLC) who previously had surgery and chemotherapy treatment, TECENTRIQ lowered the chances of cancer coming back by 34% compared to best supportive care.

Best supportive care: Care that aims to improve quality of life and prevent symptoms and side effects caused by the cancer. Also called comfort care, palliative care, and symptom management

TECENTRIQ may not work for everyone.

Start a conversation with your doctor about TECENTRIQ or learn more at TECENTRIQ.COM/NSCLC/AFTER-SURGERY

TECENTRIQ is the first immunotherapy proven to fight PD-L1+ non-small cell lung cancer after surgery and chemo.*

*Platinum-based chemotherapy

SELECT IMPORTANT SAFETY INFORMATION

Call or see your healthcare provider right away if you develop any new or worse signs or symptoms, including:

Lung problems

- cough
- shortness of breath
- chest pain

Intestinal problems

- diarrhea (loose stools) or more frequent bowel movements than usual
- stools that are black, tarry, sticky, or have blood or mucus
- severe stomach-area (abdomen) pain or tenderness

Please see full Prescribing Information and Medication Guide for additional Important Safety Information.

TECENTRIQ®
atezolizumab

WHAT IS TECENTRIQ?

TECENTRIQ is a prescription medicine used to treat:

Adults with a type of lung cancer called non-small cell lung cancer (NSCLC).

- **TECENTRIQ may be used alone as a treatment for your lung cancer:**
  - to help prevent your lung cancer from coming back after your tumor(s) has been removed by surgery and you have received platinum-based chemotherapy, **and**
  - you have stage 2 to stage 3A NSCLC (talk to your healthcare provider about what these stages mean), **and**
  - your cancer tests positive for "PD-L1".

It is not known if TECENTRIQ is safe and effective when used:

- in children for the treatment of NSCLC.

IMPORTANT SAFETY INFORMATION

What is the most important information about TECENTRIQ?

TECENTRIQ can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or life-threatening and can lead to death. You can have more than one of these problems at the same time. These problems may happen anytime during your treatment or even after your treatment has ended.

Call or see your healthcare provider right away if you develop any new or worse signs or symptoms, including:

Lung problems

- cough
- shortness of breath
- chest pain

Intestinal problems

- diarrhea (loose stools) or more frequent bowel movements than usual
- stools that are black, tarry, sticky, or have blood or mucus
- severe stomach-area (abdomen) pain or tenderness

Liver problems

- yellowing of your skin or the whites of your eyes
- severe nausea or vomiting
- pain on the right side of your stomach area (abdomen)
- dark urine (tea colored)
- bleeding or bruising more easily than normal

Hormone gland problems

- headaches that will not go away or unusual headaches
- eye sensitivity to light
- eye problems
- rapid heartbeat
- increased sweating
- extreme tiredness
- weight gain or weight loss
- feeling more hungry or thirsty than usual
- urinating more often than usual
- hair loss
- feeling cold

TECENTRIQ®
atezolizumab 840 mg | 1200 mg INJECTION FOR IV USE

IMPORTANT SAFETY INFORMATION CONT.

- constipation
- your voice gets deeper
- dizziness or fainting
- changes in mood or behavior, such as decreased sex drive, irritability, or forgetfulness

Kidney problems

- decrease in your amount of urine
- blood in your urine
- swelling of your ankles
- loss of appetite

Skin problems

- rash
- itching
- skin blistering or peeling
- painful sores or ulcers in mouth or nose, throat, or genital area
- fever or flu-like symptoms
- swollen lymph nodes

Problems can also happen in other organs.
These are not all of the signs and symptoms of immune system problems that can happen with TECENTRIQ. Call or see your healthcare provider right away for any new or worse signs or symptoms, including:

- Chest pain, irregular heartbeat, shortness of breath, or swelling of ankles
- Confusion, sleepiness, memory problems, changes in mood or behavior, stiff neck, balance problems, tingling or numbness of the arms or legs
- Double vision, blurry vision, sensitivity to light, eye pain, changes in eyesight
- Persistent or severe muscle pain or weakness, muscle cramps
- Low red blood cells, bruising

Infusion reactions that can sometimes be severe or life-threatening. Signs and symptoms of infusion reactions may include:

- chills or shaking
- itching or rash
- flushing
- shortness of breath or wheezing
- dizziness
- feeling like passing out
- fever
- back or neck pain

Complications, including graft-versus-host disease (GVHD), in people who have received a bone marrow (stem cell) transplant that uses donor stem cells (allogeneic). These complications can be serious and can lead to death. These complications may happen if you underwent transplantation either before or after being treated with TECENTRIQ. Your healthcare provider will monitor you for these complications.

Getting medical treatment right away may help keep these problems from becoming more serious. Your healthcare provider will check you for these problems during your treatment with TECENTRIQ. Your healthcare provider may treat you with corticosteroid or hormone replacement medicines. Your healthcare provider may also need to delay or completely stop treatment with TECENTRIQ if you have severe side effects.

TECENTRIQ®
atezolizumab
840 mg | 1200 mg
INJECTION FOR IV USE

IMPORTANT SAFETY INFORMATION CONT.

Before you receive TECENTRIQ, tell your healthcare provider about all of your medical conditions, including if you:

- have immune system problems such as Crohn's disease, ulcerative colitis, or lupus
- have received an organ transplant
- have received or plan to receive a stem cell transplant that uses donor stem cells (allogeneic)
- have received radiation treatment to your chest area
- have a condition that affects your nervous system, such as myasthenia gravis or Guillain-Barré syndrome
- are pregnant or plan to become pregnant. TECENTRIQ can harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with TECENTRIQ. **Females who are able to become pregnant:**
  - Your healthcare provider should do a pregnancy test before you start treatment with TECENTRIQ.
  - You should use an effective method of birth control during your treatment and for at least 5 months after the last dose of TECENTRIQ.
- are breastfeeding or plan to breastfeed. It is not known if TECENTRIQ passes into your breast milk. Do not breastfeed during treatment and for at least 5 months after the last dose of TECENTRIQ.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

The most common side effects of TECENTRIQ when used alone include:

- feeling tired or weak
- decreased appetite
- nausea
- cough
- shortness of breath

TECENTRIQ may cause fertility problems in females, which may affect the ability to have children. Talk to your healthcare provider if you have concerns about fertility.

These are not all the possible side effects of TECENTRIQ. Ask your healthcare provider or pharmacist for more information about the benefits and side effects of TECENTRIQ.

You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.

Please see accompanying full Prescribing Information and Medication Guide for additional Important Safety Information.

Genentech
A Member of the Roche Group

M-US-00013039(v2.0)

TECENTRIQ®
atezolizumab 840 mg | 1200 mg INJECTION FOR IV USE